Page last updated: 2024-12-07

4'-phosphopantetheine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-Phosphopantetheine (4'-PP) is a crucial cofactor in a wide array of metabolic pathways, serving as a prosthetic group for acyl carrier proteins (ACPs) and phosphopantetheinyl transferases (PPTases). It is a derivative of pantothenic acid (vitamin B5) and is synthesized in a two-step process. First, pantothenic acid is converted to pantetheine by the enzyme pantothenate kinase. Then, pantetheine is phosphorylated by pantetheine kinase to form 4'-PP. 4'-PP is essential for the proper function of a variety of enzymes involved in fatty acid biosynthesis, polyketide biosynthesis, non-ribosomal peptide synthesis, and other important metabolic processes. It plays a critical role in the attachment and transfer of acyl groups during these reactions, acting as a swinging arm to deliver activated substrates to the active site of the enzyme. Due to its central role in metabolism, 4'-PP has been a target of study in various fields, including: 1) understanding the mechanisms of enzyme activity and regulation in diverse metabolic pathways, 2) developing novel antibiotics that target bacterial fatty acid biosynthesis, and 3) exploring the potential of 4'-PP analogs as therapeutic agents for diseases such as cancer and diabetes.

D-pantetheine 4'-phosphate : Pantetheine 4'-phosphate with D (R) configuration at the 2' position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID115254
CHEBI ID4222
SCHEMBL ID106050
MeSH IDM0044102

Synonyms (36)

Synonym
2226-71-3
psh-4'-p
pantotheine-4'-phosphate
PNS ,
C01134
pantetheine 4'-phosphate
phosphopantetheine
d-pantetheine 4'-phosphate
4'-phosphopantetheine
DB03912
(2r)-2-hydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-4-(phosphonooxy)butanamide
pantetheine-4'-phosphate
[(3r)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] dihydrogen phosphate
CHEBI:4222
n(3)-[(2r)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-n-(2-sulfanylethyl)-beta-alaninamide
o(4)-phosphono-d-pantethein
nm39wu8ofm ,
butanamide, 2-hydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-4-(phosphonooxy)-, (r)-
unii-nm39wu8ofm
pantetheine phosphate
butyramide, 2,4-dihydroxy-n-(2-(2-mercaptoethylcarbamoyl)ethyl)-3,3-dimethyl-, 4-phosphate
butanamide, 2-hydroxy-n-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-4-(phosphonooxy)-, (2r)-
SCHEMBL106050
5pd ,
phospho-pantotheine
4'-phosphopantotheine
n~3~-[(2r)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-n-(2-sulfanylethyl)-beta-alaninamide
DTXSID30897420
(3r)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl dihydrogen phosphate
[3-hydroxy-2,2-dimethyl-3-[2-(2-sulfanylethylcarbamoyl)ethylcarbamoyl]propoxy]phosphonicacid
JDMUPRLRUUMCTL-VIFPVBQESA-N
Q6590391
[(3r)-3-hydroxy-2,2-dimethyl-3-({2-[(2-sulfanylethyl)carbamoyl]ethyl}carbamoyl)propoxy]phosphonic acid
STR08840
AMY480
[3-hydroxy-2,2-dimethyl-3-[2-(2-sulfanylethylcarbamoyl)ethylcarbamoyl]propoxy]phosphonic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" An effect on bacterial burden was demonstrated in mouse lung and thigh infection models, but further optimization of dosing requirements and compound properties is needed before these compounds can be considered for progress into clinical development."( Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy.
Brock, J; Chen, B; de Jonge, BL; Gao, N; Gu, RF; Hajec, L; Holt, E; Hutchings, K; Huynh, H; Johnstone, M; Kutschke, A; Laganas, V; Lahiri, SD; Livchak, S; McKinney, D; Nash, TJ; Neckermann, G; Ni, H; San Martin, M; Thresher, J; Utley, L; Walkup, GK, 2013
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
prosthetic groupA tightly bound, specific nonpolypeptide unit in a protein determining and involved in its biological activity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pantetheine 4'-phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Biochemical pathways: part I0466

Research

Studies (129)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (14.73)18.7374
1990's24 (18.60)18.2507
2000's51 (39.53)29.6817
2010's27 (20.93)24.3611
2020's8 (6.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.47 (24.57)
Research Supply Index4.87 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other125 (96.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]